Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Multiple antigen peptide (MAP) vaccine and application thereof

A vaccine, HLA-A2 technology, applied in medical preparations containing active ingredients, antibody medical ingredients, anti-tumor drugs, etc., can solve the problems of weak immunogenicity, single structure, small molecular weight, etc. The effect of obvious tumor activity and increased number

Inactive Publication Date: 2011-03-30
THE SECOND AFFILIATED HOSPITAL ARMY MEDICAL UNIV
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, peptide vaccines often have their shortcomings: the biggest problem is that a peptide vaccine can only represent one CTL epitope, has a small molecular weight, a single structure, weak immunogenicity, and is easily degraded in the body
However, the MAP vaccine based on the CTL epitope of hTERT has not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Multiple antigen peptide (MAP) vaccine and application thereof
  • Multiple antigen peptide (MAP) vaccine and application thereof
  • Multiple antigen peptide (MAP) vaccine and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] Example 1 Design of hTERT dominant T cell epitope MAP vaccine

[0058] Since more than 75% of the population is HLA-A2 restricted, the A2 restricted epitope P540 (ILAKFLHWL, Vonderheide RH, Hahn WC, Schultze JL, Nadler LM.The telomerase catalytic subunit is a widely expressed tumor-associated Antigen recognized by cytotoxic T lymphocytes. Immunity 1999; 10:673-679)-SEQ IDNO: 1, P865 (RLVDDFLLV, Minev B, Hipp J, Firat H, Schmidt JD, Langlade-Demoyen P, Zanetti M. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans.Proc Natl Acad Sci USA 2000; 97:4796-4801)-SEQID NO: 2, recessive epitope heteromorphic peptide P572Y (YLFFYRKSV, Scardino A, Gross DA, Alves P, Schultze JL, Graff- Dubois S, Faure O, Tourdot S, Chouaib S, Nadler LM, Lemonnier FA, Vonderheide RH, Cardoso AA, Kosmatopoulos K. HER-2 / neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J. Immunol 2002; 168:5900-5906)-SEQ ID NO: 3 Design its four-branch...

Embodiment 2

[0059] Example 2 Synthesis of hTERT dominant T cell epitope MAP vaccine

[0060] 1. Synthesis and purification of MAP peptide (completed by Shanghai Qiangyao Biotechnology Co., Ltd.): standard Fmoc method was adopted, and arginine was coupled twice; high-pressure liquid chromatography (RP-HPLC) method was used to The molecular weight of the purified polypeptide was determined on an API2000 mass spectrometer; the purified collected solution was evaporated to complete dryness or evaporated to 1-2ml at room temperature under low pressure, and then precipitated with 50ml of ether, collected by a glass sand funnel, and dried in vacuo to obtain Pure peptides were stored at -20°C for later use.

[0061] 2. The identification of MAP peptide: Adopt reverse phase high-pressure liquid chromatography (RP-HPLC) to identify its purity (such as Figure 2-7 shown), using liquid chromatography / mass spectrometry (LC / MS) to identify its molecular weight (such as Figure 8-13 shown).

Embodiment 3

[0062] Example 3 In vitro antitumor activity of human hTERT dominant T cell epitope MAP vaccine

[0063]1. Preparation of human peripheral blood-derived dendritic cells: The mononuclear cells from the peripheral blood of HLA-A2 positive healthy blood donors (provided by the Department of Blood Transfusion, Southwest Hospital, Third Military Medical University) were separated by Ficoll-Hypaque gravity gradient centrifugation. Cells resuspended in RPMI-1640 medium (purchased from Hyclone) containing 10% fetal bovine serum (purchased from Hyclone) were placed in a 37°C incubator for 2 hours, and non-adherent cells were collected and frozen for future use. For the preparation of effector cells later. Adhered cells were further cultured in RPMI-1640 medium containing 10% fetal bovine serum, and recombinant human mononuclear macrophage colony-stimulating factor (rhGM-CSF) and recombinant human interleukin-4 (rhIL-4) were added to it (both purchased from R&D System, Inc., USA), so...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a multiple antigen peptide (MAP) vaccine and application thereof. The peptide sequence of the MAP vaccine is shown as SEQ ID NO:1-3. The MAP vaccine is a human telomerase reverse transcriptase (hTERT)-based T cell epitope MAP vaccine. The peptides shown as the SEQ ID NO:1-3 are selected from HLA-A2 restrictive dominant epitopes P540 and P865 and recessive epitope distinct peptide P572Y. The invention also provides an anti-tumor preparation. The anti-tumor preparation comprises the MAP vaccine. The MAP vaccine provided by the invention has obvious anti-tumor activity and does not have killing effect on tumor cells only expressing HLA-A2+ or hTERT+. A cytotoxic T lymphocyte (CTL) reaction induced by the MAP vaccine does not have any killing side effect on autologous lymphocytes and dendritic cells (DC), so the MAP vaccine is safe to use. The number of specificity T lymphocytes activated by the MAP vaccine is increased obviously.

Description

technical field [0001] The invention relates to a biological vaccine, in particular to a MAP vaccine and its application. Background technique [0002] Malignant tumors are one of the major diseases that endanger human health, and tumor invasion and metastasis are the main causes of death in cancer patients. The efficacy of traditional surgery, radiotherapy, and chemotherapy is not satisfactory. With the in-depth study of tumor biological behavior and the rapid development of biotechnology, tumor immunotherapy-based biological therapy has become the fourth tumor treatment. Model, and tumor vaccine is an important method of tumor biological treatment. A large number of studies have proved that the effective activation of specific cytotoxic T lymphocytes (cytotoxic T lymphocytes, CTLs) by tumor vaccines is the key to active tumor immunotherapy. However, most of the tumor-associated antigens discovered so far are tissue-specific. For example, PSA only targets prostate cancer,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/00A61P35/00
Inventor 郭红杨仕明廖忠莉汤旭东宁琳红周圆圆周媛杨武晨柏健鹰张朋彬赵晓晏
Owner THE SECOND AFFILIATED HOSPITAL ARMY MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com